According to a new report published by OG Analysis, the global AI in Cell and Gene Therapy Development Market was valued at USD 520 million in 2026 and is projected to reach USD 3.87 billion by 2034, expanding at a CAGR of 28.5% during the forecast period.

Market Overview

The market is emerging as a high-value digital life sciences segment as advanced-therapy developers seek faster, more predictable, and scalable approaches to discovery, process development, manufacturing, and clinical translation. Artificial intelligence is being applied across target discovery, cell engineering, vector optimization, process development, predictive quality control, CMC analytics, clinical translation, regulatory support, and automated biomanufacturing workflows. Market growth is being supported by the complexity of cell and gene therapy pipelines, pressure to shorten development timelines, and the need to improve potency, safety, manufacturability, scale-up, and batch consistency. Machine learning, generative AI, multi-omics analytics, digital twins, computer vision, predictive manufacturing analytics, and AI workflow automation are becoming increasingly relevant across R&D and GMP operations. The market size is also benefiting from investment in AI-ready scientific data infrastructure, connected laboratories, automated cell-processing platforms, and predictive bioprocess analytics, while data standardization, model validation, regulatory acceptance, cybersecurity, talent shortages, and high implementation costs remain key adoption challenges.

Key Market Insights

●       The market forecast rises from USD 520 million in 2026 to USD 3.87 billion by 2034 at a 28.5% CAGR, reflecting rapid adoption of AI-enabled drug development, process optimization, and advanced-therapy manufacturing tools.

●       North America leads regional market share at 53% in 2026, supported by concentrated biotechnology R&D, advanced AI capabilities, strong academic ecosystems, and extensive cell and gene therapy pipelines; Asia-Pacific is positioned as the fastest-growing region.

●       Process Development is the leading application at 23.8% market share as developers use predictive modeling and digital bioprocess tools to optimize cell culture, vector yield, scale-up, manufacturing consistency, and batch performance.

●       Machine Learning leads the technology segment with 38% share, supported by broad use in target prediction, construct design, multi-omics analysis, process optimization, predictive QC, and clinical outcome modeling.

●       CGT biotech companies account for 42% of end-user demand, reflecting strong use of AI platforms to accelerate discovery, reduce development risk, improve manufacturing efficiency, and support faster clinical translation.

Market Dynamics

●       Driver: Rising complexity across cell and gene therapy discovery, vector design, cell engineering, process development, and CMC workflows is increasing demand for AI-driven prediction, experimental design, and decision-support tools.

●       Driver: Pressure to improve manufacturing consistency, potency, safety, scalability, and time-to-clinic is accelerating adoption of predictive bioprocess analytics, digital twins, automated QC, and connected manufacturing systems.

●       Opportunity: Generative AI, multi-omics analytics, AI-assisted vector optimization, virtual process modeling, and autonomous laboratory workflows create opportunities to improve therapeutic design and reduce iterative development cycles.

●       Restraint: Fragmented biological datasets, inconsistent data standards, model explainability concerns, validation requirements, and integration with legacy laboratory and GMP systems can slow enterprise-scale adoption.

●       Restraint: High implementation costs, scarce interdisciplinary talent, cybersecurity requirements, and uncertainty around regulatory acceptance of AI-supported decisions remain barriers, especially for smaller therapy developers.

●       Opportunity: Asia-Pacific offers strong growth potential as China, Japan, South Korea, and other markets expand advanced-therapy pipelines, biomanufacturing capacity, AI research capabilities, and precision-medicine investment.

●       Opportunity: Strategic collaboration among AI biotech platforms, life-science software companies, automation suppliers, CDMOs, bioprocess vendors, and therapy developers can accelerate validated AI deployment across discovery-to-manufacturing workflows.

Browse for More Information

https://www.oganalysis.com/industry-reports/ai-in-cell-and-gene-therapy-development-market

Market Segmentation

The market is segmented by application, technology, end user, and geography. By application, the industry report covers Target Discovery, Cell Engineering, Vector Optimization, Process Development, Predictive QC/CMC Analytics, Clinical Translation, and Regulatory Support; Process Development leads with 23.8% market share. By technology, Machine Learning holds the largest share at 38%, alongside Generative AI, Multi-Omics Analytics, Digital Twins, Computer Vision, Predictive Manufacturing Analytics, and AI Workflow Automation. By end user, CGT Biotech Companies lead with 42%, with additional demand from Large Pharma, CDMOs/IDMOs, Research Institutes, Hospitals/Cell Processing Centers, and CROs/Bioinformatics Providers. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America, reflecting differences in advanced-therapy pipelines, digital infrastructure, regulatory frameworks, manufacturing maturity, and investment in AI-enabled life-science development.

Regional Insights

●       North America: The region leads with 53% market share in 2026, supported by strong biotechnology and pharmaceutical R&D, advanced AI adoption, major academic and clinical research hubs, and extensive cell and gene therapy development activity.

●       Asia Pacific: The region is expected to grow fastest as China, Japan, South Korea, and other markets expand cell and gene therapy pipelines, AI-enabled drug development capabilities, precision-medicine investment, and advanced biomanufacturing infrastructure.

●       Europe: Europe represents a major market supported by advanced-therapy research, regulatory initiatives, academic-industry collaboration, digital biomanufacturing investment, and strong life-science software and automation adoption.

●       Latin America & Middle East and Africa: South and Central America remains a developing market supported by expanding biotechnology investment and clinical research, while the Middle East and Africa is emerging through investment in precision medicine, biotech research, and advanced therapeutic development.

Competitive Landscape

The market is highly innovation-driven, with key players competing through AI-ready scientific data platforms, automated bioprocessing systems, digital manufacturing software, predictive analytics, cell and gene therapy development services, and strategic co-development partnerships. Life-science software providers are building connected R&D and laboratory data environments, while automation companies and bioprocess suppliers are integrating AI into cell-processing, process control, quality monitoring, and scale-up. AI-native biotechnology companies are applying machine learning and generative models to target discovery, sequence design, vector optimization, and therapeutic engineering. Competitive positioning increasingly depends on validated data infrastructure, interoperability with GMP workflows, domain-specific models, automation depth, regulatory readiness, and the ability to support discovery-to-commercial manufacturing transitions.

Some of the key players operating in the market include Benchling, Cellares, Cytiva, Thermo Fisher Scientific, Dassault Systèmes BIOVIA, Sartorius, Ori Biotech, Cellino, Automata Technologies, Synthace, TetraScience, Scispot, Unlearn.AI, Recursion Pharmaceuticals, Insilico Medicine, Exscientia, Absci, Generate Biomedicines, Dyno Therapeutics, Form Bio, BigHat Biosciences, Owkin, Valo Health, Ginkgo Bioworks, Resilience, ElevateBio, Lonza, Charles River Laboratories, Catalent, WuXi Advanced Therapies, BioCentriq, and Fujifilm Diosynth Biotechnologies.

Recent Developments

●       May 2026: Dyno Therapeutics launched two new AI-engineered AAV capsids and expanded access to its AI platform, strengthening machine-learning-based gene-delivery vector design and rare-disease therapy development.

●       April 2026: Astellas exercised an option to license an AI-designed skeletal-muscle-targeted AAV capsid from Dyno Therapeutics, supporting next-generation gene therapy development through AI-driven biological sequence design.

●       February 2026: Made Scientific and Streamline Bio launched an early-adopter program for AI-driven robotic cell therapy manufacturing, targeting higher automation, reproducibility, scalability, and manufacturing efficiency.

●       January 2026: FDA and EMA introduced guiding principles for good AI practice in drug development, emphasizing data governance, model validation, risk management, human oversight, and lifecycle management.

●       July 2025: The AIDPATH project advanced an AI-powered automated CAR-T manufacturing platform into hospital-based testing, supporting decentralized production of genetically engineered immune cells with improved process control.

●       June 2025: Invetech and AiCella announced a strategic collaboration on AI-enabled cell therapy process development, combining manufacturing automation with AI-based process optimization to improve scalability and production outcomes.